Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1389 | HOME-CoV rule implementation Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions
Description: Measure COVID-19 infection risk score based on PCR Positive Test
Measure: Predictors of post COVID-19 complications and predictors of hospitalization Time: 1 DayDescription: Measure COVID-19 infection risk score based on health symptoms
Measure: Health symptom score Time: 1 DayDescription: Measure COVID-19 infection high risk score based on vital signs SpO2 <94%
Measure: Vital signs SpO2 score Time: 1 DayDescription: Measure COVID-19 infection high risk score based on Height 0.15 meters and Weight of 122 Kgs
Measure: Vital signs BMI score of 40 kg/m2 Time: 1 DayDescription: Measure COVID-19 infection high risk score based on chronic illness response; Yes on uncontrolled Asthma, COPD, Hypertension, T2DM
Measure: Chronic Illness score Time: 1 DayDescription: Measure COVID-19 infection risk score based on mental health assessment for Depression
Measure: Mental health assessment high score >11 on PHQ9 Depression score Time: 1 DayDescription: Measure COVID-19 infection risk score based on mental health assessment for Anxiety
Measure: Mental health assessment high score >11 on GAD 7 Anxiety score Time: 1 DayDescription: Measure hospital admissions in PCR positive COVID 19 subjects within 48 hours who are in Stage I of the disease process
Measure: Evaluate a treatment strategy with ECL-19 Time: 1 DayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports